Advancing the frontier of endocannabinoid biotechnology.
Sonas Pharma is a startup biotech company dedicated to the development of innovative endocannabinoid-based therapies.
Our primary focus is on engineering groundbreaking medical solutions designed to treat epilepsy and metabolic disease through targeted high-precision pharmaceutical innovation.
Solving Critical Endocannabinoid Development Challenges
Overcoming Drug Development Barriers
Addressing fundamental challenges in drug development through targeted innovative molecular engineering to improve upon the properties of the parent molecule
Enhanced Pharmacology and Safety
Superior efficacy, receptor selectivity, and optimized ADME properties minimize off-target effects and drug-drug interactions
Robust Intellectual Property Position
Comprehensive patent portfolio with composition of matter protection ensuring long-term market exclusivity and competitive advantage
Clear Path to Commercial Success
De-risked development strategy leveraging validated endpoints and established regulatory pathways to accelerate market entry
Evidence-Led Innovation for Neuro and Metabolic Care
Sonas Pharma is pioneered by global experts in endocannabinoid science. We refine targeted molecules to address the unmet medical needs of patients living with epilepsy and metabolic disease, ensuring that every therapy is built on more than just hope—it's built on measurable clinical data.
Latest News
February 26, 2026
Pre-seed funding round closed
Sonas Pharma today announced it has closed a pre-seed funding round
investment round, led by SFC Capital with participation from Clarendon Fund Managers. This funding marks an important milestone in Sonas Pharma’s mission to build safer, mechanism-driven endocannabinoid system based therapeutics, leveraging modern insights in GPCR pharmacology, peripheral restriction, and rational drug design.
February 20, 2026
Sonas Pharma presents at Talman Group cannabis networking event
Sonas Pharma recently presented at the Talman Group event in Zurich, sharing our vision for next‑generation CB1R‑focused therapeutics in obesity and epilepsy. We discussed our cannabinoid and mechanism‑first metabolic drug development approach, safety‑driven peripheral CB1R modulation, and our emerging epilepsy program, while building relationships across Europe’s investment ecosystem.
january 15, 2026
International Patent WO 2026/013418 Published
Sonas Pharma has filed an international patent for a new generation of cannabinoid medicines designed to go beyond CBD. While CBD proved the power of the cannabinoid pathway in epilepsy and created a blockbuster drug, it is still a first‑generation solution with clear limits: heavy dose burden, metabolic waste, and serious drug–drug interactions. Our newly published patent marks the next step in cannabinoid therapeutics — engineered for greater precision, efficiency and clinical impact.